Conversion by Michael Hoffman of 140449 shares of Onconova Therapeutics
Macroaxis does not monitor all media channels or aggregates social signals for Onconova Therapeutics. But even though we do not provide professional-grade financial sentiment analysis on Onconova Therapeutics, we do publish noise-free headlines that can be used to derive useful patterns or even a trading strategy for Onconova Therapeutics. Additionally take a look at Your Equity Center.
Filed transaction by Onconova Therapeutics Inc director. Derivative codes conversion of derivative security
|This media report from MacroaxisInsider distributed on March 8, 2018 was a factor to the next trading day price appreciation.The trading delta at closing time against the next closing price was 0.94% . The trading delta at closing time when the story was published against the current closing price is 247.17% .|
Similar stores for Onconova Therapeutics
Investment Analysts Weekly Ratings Updates for Onconova Therapeutics Fairfield CurrentSeveral brokerages have updated their recommendations and price targets on shares of Onconova Therapeutics in the last few weeks ...
Onconova Therapeutics Reports Phase 2 Trial of Oral Rigosertib in Combination with Azacitidine in Myelodysplastic Syndromes StreetInsider.comGet instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here. Onconova Therapeutics, Inc. ...
Onconova Therapeutics The Many Strengths Of INSPIRE Seeking AlphaOnconovas INSPIRE confirmatory trial is a fascinating construct. Its cutting-edge Adaptive features make it resilient to failure. Valuation of Onconova assumin.
Baseball Daily NewsFull coverage
NYSE DAILY Full coverage
Thorold NewsFull coverage
StreetInsider.comOnconova Therapeutics, Inc. EPS Estimated At -0.05 Thorold NewsFull coverage
Fairfield CurrentFull coverage
Analyst JournalFull coverage
Alpha Beta StockFull coverage
Book Value Per Share